| DATE: February 6, 2024 |
| --- |
| **TOPIC** | **DISCUSSION/ACTION** | **FOLLOW-UP** |
| Housekeeping announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a poll link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Strawpoll sent with these minutes |
| Guidelines in-progress | Guidelines* *CYP3A5*/Tacrolimus – In evidence review
* *CYP2D6*/Antipsychotics – In evidence review/working on recommendations; more drugs were added
* *NAT2*/Hydralazine – Drafting guideline
* *UGT1A1*/irinotecan- Authorship plan underway
* *DPYD*/fluoropyrimidines- Evidence review underway
* *TPMT-NUDT15*/thiopurines update - Evidence review almost complete
* *CYP2D6*/ondansetron - Authorship plan underway
* *HLA* Guideline – Hoping to begin in summer 2025.
 | Kelly will continue to updateTo see the guidelines currently being developed go to: <https://cpicpgx.org/prioritization-of-cpic-guidelines/> |
| CPIC *HLA* Guideline Call for Authors | Kelly requested authors for the upcoming CPIC *HLA* guideline with expertise in this area. Of special need are authors in countries outside of the USA. | Email Kelly (kelly.caudle@stjude.org) if you would like to self-nomination or nominate a colleague  |
| Updated ClinPGx/CPIC 2025 Meeting Dates | The dates for the [Clin PGx/CPIC 2025 meeting](https://cpicpgx.org/meetings/) in Missoula, MT were changed to September 10-12, 2025.  | Please update your calendar! |
| Pharmacogenomics of Hereditary Disease | Josiah Allen, Pharm D, St. Elizabeth Healthcare, and Benjamin Duong, PharmD, Nemours Children’s Health, presented “Enigmatic Pharmacogenomic Implications within Clinical Genomics Secondary Findings”.  |  |